GOLDEN-EURO
Champagnen flyder, og fejringen er godt undervejs i Golden Euro-casinoet, efter en heldig spiller ramte jackpotten og landede en monstergevinst på 3.746.291 €.
Spillerens gevinst blev udløst på Realtime Gamings enormt populære spillemaskine Aztec Millions og er den største gevinst nogensinde, der er blevet registreret på det progressive jackpotspil og hos Golden Euro.
Den 49-årige spiller foretog en indbetaling med kreditkort på 27 € for at starte sin session og for at få Golden Euros højtelskede 50 % indbetalingsmatchbonus, hvilket gave hende derfor 54 € at spille med.
Men selve gevinsten kom fra en lille indsats på blot 5 €, som hun foretog på sin smartphone - efterhånden som hjulene stoppede og jackpotten blev udløst, blev spilleren øjeblikkeligt millionær.
Adrian Berger fra Golden Euro Casino udtalte: "Vi er superglade for, at en af vores spillere landende den største jackpotgevinst nogensinde på Realtime Gamings Aztec Millions.
"Jeg talte med spilleren kort tid efter at have bekræftet hendes gevinst, og hun var i den syvende himmel, selvom det faktum, at hun nu er multimillionær, endnu ikke er gået helt op for hende.
"Disse gevinster er lige præcis, hvad Golden Euro handler om – vi vil gerne give vores spillere en sjov og underholdende online casinooplevelse med livsændrende gevinster, der kun er ét spin væk.
"Jeg vil endnu en gang lykønske vores heldige spiller, og jeg glæder mig til at annoncere flere store vindere og jackpotvindere hos Golden Euro i de kommende måneder."
Aztec Millions-jackpotten er atter på højkant og har allerede rundet over 1 million euro, så husk at prøve lykken og se, om du bliver den næste Golden Euro-millionær.
Jackpotværdien stiger hurtigt, fordi det er en progressiv netværksjackpot, hvilket betyder, at alle spillere, som spiller spillet på tværs af alle de casinoer, som tilbyder spillet, bidrager til jackpottens samlede sum.
Aztec Millions kan spilles på Golden Euro via download, øjeblikkeligt spil og i mobilens webbrowser.
Golden Euro Casino blev grundlagt i 2012 og er siden blevet en af de mest populære sider takket være sit fantastiske udvalg af spil, generøse bonusser og venlige kundesupport.
SLUT
Afsenders bemærkning:
Om Golden Euro Casino:
https://www.goldeneuro.com/en/
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210413005871/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum